Caplyta (lumateperone) for bipolar depression: state of practice

Novelty of the mechanism

Lumateperone is called a "multimodal" antipsychotic because it acts across serotonin, dopamine, and glutamate systems in a distinctive pattern:

• 5-HT2A antagonism 60-fold more potent than D2 antagonism
• Presynaptic D2 partial agonism (reduces dopamine release in mesolimbic pathway)
• Postsynaptic D2 antagonism at higher receptor occupancy
• D1 agonism (increases glutamate signaling in prefrontal cortex)
• SERT inhibition (antidepressant activity)

The theoretical claim is that this profile treats psychosis (via D2 modulation), depression (via SERT and D1), and cognition (via D1 and glutamate) with less metabolic burden than other atypicals.

Trial data

Schizophrenia (original 2019 approval):

• STUDY-005 and STUDY-301: efficacy at 42 mg vs placebo
• Effect size comparable to other atypicals
• Minimal weight gain, prolactin, or EPS

Bipolar depression monotherapy (Study 401 and Study 404):

• Effect size on Montgomery-Asberg Depression Rating Scale (MADRS) at 6 weeks
• Statistical superiority over placebo
• Both bipolar I and II patients included
• Weight change comparable to placebo

Bipolar depression adjunctive (Study 402):

• Adjunctive to lithium or valproate
• Effect on MADRS at 6 weeks
• Similar side effect profile to monotherapy

Dosing

• 42 mg once daily
• Take with food (bioavailability affected)
• No titration required
• No dose adjustment for age (used in adults 18+)
• Renal impairment: no adjustment for mild to moderate; caution in severe
• Hepatic impairment: reduce dose for moderate to severe

Tolerability

Common (5 to 10 percent):

• Somnolence
• Nausea
• Dry mouth
• Headache

Uncommon but notable:

• Weight change: near placebo in trials
• Metabolic changes: minimal
• EPS: minimal (comparable to placebo)
• Prolactin: minimal elevation
• QTc: minimal
• Sexual side effects: low
• Sedation: mild to moderate

Contraindications:

• Concurrent CYP3A4 strong inhibitors (dose adjust)
• Concurrent CYP3A4 strong inducers (avoid)

Where lumateperone fits

In bipolar depression:

• Reasonable first-line for patients where weight, metabolic, and sedation concerns are top priorities
• Comparable efficacy to quetiapine or lurasidone with better tolerability
• Cost is a barrier; branded only

In schizophrenia:

• Alternative to quetiapine, aripiprazole, or brexpiprazole for lower-metabolic-risk profile
• Not shown superior in efficacy to established alternatives

Vs quetiapine:

• Similar efficacy for bipolar depression
• Much better weight and sedation profile
• Much higher cost

Vs lurasidone (Latuda):

• Similar efficacy for bipolar depression
• Lumateperone does not require food for absorption (lurasidone does)
• Cost and access similar

Cost and access

List price around $1,900 per month. Commercial insurance often requires PA. Manufacturer copay assistance available for eligible commercially insured patients.

Common questions

Is Caplyta better than quetiapine for bipolar depression? Comparable efficacy in indirect comparisons. Better metabolic and sedation profile. Substantially higher cost. Choice often driven by insurance and prior response.

Can Caplyta be used with lithium or valproate? Yes, FDA-approved for adjunctive use with lithium or valproate for bipolar I depression.

Does Caplyta cause weight gain? Weight change was near placebo in trials. Real-world data continues to support minimal weight gain vs other atypicals.

Is there a generic? Not yet (as of mid-2026). Patent extends into 2030s.

Can Caplyta be used in schizoaffective disorder? Off-label. FDA indication is schizophrenia and bipolar depression. Used clinically for related presentations.

How is Caplyta different from Cobenfy? Different mechanisms. Caplyta is a partial-agonist / 5-HT2A / SERT / D1 drug with modest D2 activity. Cobenfy is muscarinic M1/M4 agonism with no D2 effect. Both minimize traditional D2 side effects but through different routes. See our Cobenfy state of practice.

When should Caplyta not be used? Severe hepatic impairment, concurrent strong CYP3A4 inducers, or in patients where cost is prohibitive without alternatives.

Sources

• Vanover KE, Davis RE, Zhou Y, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598-605.
• Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098-1106.
• Caplyta (lumateperone) prescribing information. Intra-Cellular Therapies; approved December 2021 for bipolar depression.
• Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(4):349-358.